How dersimelagon, Scenesse and bitopertin address phototoxic pain through different biological strategies.
Related Analysis
For the strategic and deal context, read my main BP analysis: [LEO Pharma Bets Up to $435 Million on Oral Therapy for Rare Sunlight-Induced Pain]
Science at a Glance
| Item | Dersimelagon | Scenesse | Bitopertin |
|---|---|---|---|
| Developer | Tanabe Pharma / LEO Pharma | Clinuvel Pharmaceuticals | Disc Medicine |
| Modality | Oral small molecule | Subcutaneous implant | Oral small molecule |
| Target | Melanocortin-1 receptor (MC1R) | Melanocortin-1 receptor (MC1R) | Glycine transporter 1 (GlyT1) |
| Core strategy | Increase photoprotection | Increase photoprotection | Reduce PPIX production |
| Indication | Erythropoietic protoporphyria (EPP) / X-linked protoporphyria (XLP) | Erythropoietic protoporphyria (EPP) | Erythropoietic protoporphyria (EPP); Phase 3 also includes XLP |
| Status | NDA submitted | FDA approved | Phase 3; CRL response planned |
The three therapies approach the same clinical problem from two directions: dersimelagon and Scenesse increase photoprotection, while bitopertin aims to reduce the phototoxic metabolite itself.
Why Light Causes Severe Pain in EPP and XLP
Erythropoietic protoporphyria (EPP) is most commonly caused by reduced activity of ferrochelatase (FECH), the final enzyme in heme synthesis. X-linked protoporphyria (XLP) instead results from gain-of-function variants in 5-aminolevulinate synthase 2 (ALAS2).
Despite different genetic causes, both disorders lead to excessive accumulation of protoporphyrin IX (PPIX).
When PPIX absorbs visible light, it generates reactive oxygen species and triggers acute phototoxic tissue injury.
FECH deficiency or ALAS2 overactivity → PPIX accumulation → light exposure → oxidative injury → severe pain
This creates two therapeutic opportunities: reduce PPIX production or increase protection against light-induced damage.
1. Dersimelagon — Oral MC1R Activation
Dersimelagon is an orally administered, selective melanocortin-1 receptor (MC1R) agonist.
MC1R activation promotes melanogenesis and increased protective pigmentation, helping patients tolerate longer exposure to light without directly reducing PPIX production.
Dersimelagon → MC1R activation → protective pigmentation ↑ → photoprotection ↑ → light tolerance ↑
The Phase 3 INSPIRE study enrolled 165 adults and adolescents with EPP or XLP and met its primary endpoint. Tanabe subsequently submitted a U.S. New Drug Application (NDA) for both diseases on June 30, 2026. (Dersimelagon Phase 3 and regulatory update)
2. Scenesse — The Established MC1R Strategy
Scenesse (afamelanotide) works through the same broad biological pathway.
Afamelanotide is an analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates MC1R and increases pigmentation and photoprotection.
Scenesse → MC1R activation → protective pigmentation ↑ → pain-free light exposure ↑
The key practical difference is administration. Scenesse is a 16 mg subcutaneous implant administered every two months. The FDA approved it in 2019 specifically to increase pain-free light exposure in adult patients with EPP. (FDA Scenesse prescribing information)
3. Bitopertin — Reducing PPIX at Its Source
Bitopertin takes a fundamentally different approach.
It inhibits glycine transporter 1 (GlyT1), limiting glycine uptake into developing erythroid cells. Because glycine is an essential starting substrate for heme biosynthesis, this reduces pathway flux and lowers PPIX production.
Bitopertin → GlyT1 inhibition → glycine uptake ↓ → heme synthesis flux ↓ → PPIX ↓ → phototoxicity ↓
Rather than increasing tolerance to light, bitopertin therefore aims to reduce the biochemical source of phototoxicity. (Disc Medicine bitopertin mechanism)
Bitopertin received a Complete Response Letter (CRL) from the FDA in February 2026 for its EPP NDA. Disc Medicine subsequently aligned with the FDA that a successful Phase 3 APOLLO study could support its CRL response and potentially traditional approval. APOLLO enrolled 183 patients with EPP or XLP, with topline results expected in Q4 2026. (Disc Medicine regulatory update)
Three Mechanisms, One Clinical Goal
| Therapy | Where it acts | Biological effect | Practical distinction |
|---|---|---|---|
| Dersimelagon | MC1R / skin | Photoprotection ↑ | Oral |
| Scenesse | MC1R / skin | Photoprotection ↑ | Implant every 2 months |
| Bitopertin | Erythroid heme pathway | PPIX production ↓ | Oral |
The central distinction is simple: dersimelagon and Scenesse help the skin tolerate light, while bitopertin tries to reduce the molecule that makes light dangerous in the first place.
BP Science View
Dersimelagon and Scenesse compete within the same MC1R-driven photoprotection strategy, with oral administration providing dersimelagon a potentially meaningful convenience advantage over an implant.
Bitopertin represents a more fundamentally different approach. By lowering PPIX production, it aims to intervene upstream of the phototoxic reaction rather than strengthening protection against incoming light.
The emerging EPP landscape may therefore become less about which drug simply increases light tolerance and more about whether photoprotection or PPIX reduction produces the stronger balance of efficacy, convenience and long-term disease control.
About BP Science
BP Science explains the biology, mechanisms, modalities and technology landscapes behind emerging biopharma therapies.
Leave a Reply